Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
These hilarious notices will make you do a double take
Public signs should usually be able to point you in the right direction, but some are clearly just t2024-05-21Experts urge stronger support for biodiversity conservation
Financial support is crucial for advancing biodiversity conservation, which is a critical part of gl2024-05-216 new plant species discovered in China's Guangxi
Six new plant species have been discovered in south China's Guangxi Zhuang Autonomous Region, ac2024-05-21Jordan condemns Israeli settlers' assault on Jordanian aid convoy to Gaza
Jordan's Foreign Ministry on Wednesday strongly condemned the assault by extremist Israeli settl2024-05-21Ricky Stenhouse punching Kyle Busch could lead to suspension
NORTH WILKESBORO, N.C. (AP) — Ricky Stenhouse Jr. threw a right hook at Kyle Busch, and suddenly, an2024-05-21Police in Fort Worth say four children are among six people wounded in a drive
FORT WORTH, Texas (AP) — Four children are among six people wounded in a drive-by shooting at a Fort2024-05-21
atest comment